11 Result(s)

Article

A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer

Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer. However, there are limited...

Tomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, Taiga Otsuka… in Scientific Reports (2024)

Article

Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay

Circulating tumor DNA (ctDNA) is the fraction of cell-free DNA in patient blood that originates from a tumor. Advances in DNA sequencing technologies and our understanding of the molecular biology of tumors ha...

Tadayoshi Hashimoto, Yoshiaki Nakamura… in International Journal of Clinical Oncology (2024)

Article

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa… in Scientific Reports (2024)

Article

Correction: Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study

Taro Shibuki, Mitsuhito Sasaki, Shota Yamaguchi, Kanae Inoue… in Radiation Oncology (2023)

Article

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role ...

Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka… in Scientific Reports (2023)

Article

Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study

Patients with unresectable pancreatic cancer (PC) sometimes experience gastrointestinal bleeding (GIB) due to tumor invasion of the gastrointestinal tract (tumor bleeding); no standard treatment has been estab...

Taro Shibuki, Mitsuhito Sasaki, Shota Yamaguchi, Kanae Inoue… in Radiation Oncology (2023)

Article

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflamma...

Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa… in Scientific Reports (2023)

Article

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX.

Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda… in BMC Cancer (2022)

Article

Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

In the original publication, Fig. 3 has been published incorrectly.

Taiga Otsuka, Tsuyoshi Shirakawa… in International Journal of Clinical Oncology (2021)